Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092527 · ClinicalTrials.gov registry record · Phase 4
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
A Phase 4 study of Transgenderism and Reproductive Issues, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07092527 is a Phase 4 study of Transgenderism and Reproductive Issues that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 80 participants, above the 54-participant average among 5 other Transgenderism trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07092527, a Phase 4 study of Transgenderism and Reproductive Issues, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
Conditions Studied
Interventions
- DRUG Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
Study Locations (1)
California
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07092527
The ClinicalTrials.gov registry entry for NCT07092527 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 54-participant average among 5 other Transgenderism trials with a reported enrollment target (48% higher). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Transgenderism appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution is the first listed.
NCT07092527 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07092527 about?
NCT07092527 is a clinical study titled "Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version". This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
What is the current status of trial NCT07092527?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2025-12-05. Estimated completion is 2028-11-30.
What conditions does trial NCT07092527 study?
This clinical trial studies the following conditions: Transgenderism, Reproductive Issues.
What interventions are being tested in trial NCT07092527?
The interventions under investigation include: Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT07092527?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092527 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgenderism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puberty Suppression and Cardiometabolic Health
RECRUITING
-
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RECRUITING
-
Cardiometabolic Health in Transgender Males
ACTIVE NOT RECRUITING
-
Transgender Estradiol Affirming Therapy
COMPLETED · Phase 2
-
Effect of Hormone Therapy on Renal Function
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.